Medpace Holdings, Inc. (MEDP) Hits Fresh High: Is There Still Room to Run?

Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Investment Research • 10 hours ago

Here's Why Medpace (MEDP) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Oct 26, 2026

All You Need to Know About Medpace (MEDP) Rating Upgrade to Buy

Medpace (MEDP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Oct 26, 2026

Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes"

Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Investment Research • Oct 26, 2026

Medpace: Downgrade 'Hold' Revenue Growth Guidance Change And Slightly Lower Backlog Conversion Rate

Medpace Holdings is downgraded from "Buy" to "Hold" due to decelerating growth metrics and underwhelming forward guidance. Q3 2026 Net New Business Awards rose just 10.6%, a sharp slowdown from Q2's 28.2% growth, signaling weaker contract momentum. Revenue growth in Q3 2026 was 8.5% to $716M, below the prior quarter's 17.2% pace and only modestly above consensus.

Seeking Alpha • Oct 25, 2026

Medpace: 3 Key Takeaways for Long-Term Investors

Net new business awards reached $873 million in the third quarter. Ending backlog reached $3.2 billion, up 5.6% year over year.

The Motley Fool • Oct 23, 2026

Medpace Q3 Earnings Call Highlights

Medpace NASDAQ: MEDP reported third-quarter 2026 revenue growth of 8.5% and record net new business awards, while management said the clinical research organization continues to see a strong operating environment marked by healthy request-for-proposal activity, initial award notifications and win rates.

MarketBeat • Oct 22, 2026

Medpace Holdings, Inc. (MEDP) Q3 2026 Earnings Call Transcript

Medpace Holdings, Inc. ( MEDP ) Q3 2026 Earnings Call October 22, 2026 9:00 AM EDT Company Participants David Ruhe - Associate Director of Financial Planning & Analysis August Troendle - CEO, President & Chairman Kevin Brady - CFO & Treasurer Conference Call Participants Michael Cherny - Leerink Partners LLC, Research Division Jailendra Singh - Truist Securities, Inc., Research Division Tucker Remmers - UBS Investment Bank, Research Division Ann Hynes - Mizuho Securities USA LLC, Research Division Justin Bowers - Deutsche Bank AG, Research Division Ryan Halsted - RBC Capital Markets, Research Division David Windley - Jefferies LLC, Research Division Christine Rains - William Blair & Company L.L.C., Research Division Eric Coldwell - Robert W.

Seeking Alpha • Oct 22, 2026

Medpace Slips Despite Third-Quarter Beat, Solid Earnings Outlook

Medpace stock slipped late Wednesday despite beating third-quarter forecasts and issuing an above-Street view for 2026 earnings.

Investors Business Daily • Oct 21, 2026

Medpace Holdings, Inc. Reports Third Quarter 2026 Results

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Results Revenue for the three months ended September 30, 2026 increased 8.5% to $716.0 million, compared to $659.9 million for the comparable prior-year period. On a constant currency basis, revenue for the third quarter of 2026 increased 8.6% compared to the third quarter of 2025. Backlog as of September 30.

Business Wire • Oct 21, 2026